Classic Tug of War between the long term investor who is understandably disappointed in the price and moving on and those shares offered being picked up by traders with a brand new time horizon.
CUBT has an impressive pipeline with a NIH clinical trial for the macular degeneration just announced. Unfortunately, in a quiet period, the PR came out as a whisper.
Looking forward to that Quiet Period ending soon so there can be a little more noise about what the company is doing:
Infectious Diseases
IMT505 Rabies (1)
Priority Review Voucher (PRV) Eligible
Infectious Diseases
COVID Vaccine with IMT504 Adjuvant
COVID 19 in Kidney Failure Patients (2)
Oncology
CUBT906- CD56 Monoclonal Antibody ADC Glioblastoma (2)
Degenerative Eye Disease
Metformin Reformulation
Age-Related Macular Degeneration (1)
(1) Each of these therapeutics have undergone certain toxicology and pharmacokinetics animal studies. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.
(2) Each of these therapeutics have not undergone pre-clinical development. Please see further description in “Product Development” below for a further description of the development of each indicated therapeutic.
JMHO.
News 
Market Data 
Discover 
